Teva Under Federal Scrutiny Over Potential FCA Breaches
The Israeli drugmaker said the U.S. attorney in New York demanded on Jan. 8 to see documents related to sales, marketing and promotion of two of its drugs, the top-selling Copaxone and Azilect. Teva said it is complying with the subpoenas.
Representatives for Teva did not immediately respond to requests for...
To view the full article, register now.